In a multicenter phase I trial (NCT01781429), patients with NRAS, BRAF or MEK-mutated advanced solid tumor were treated with ulixertinib, an ERK1/2 inhibitor, to identify its safeness and clinical activity. The results demonstrated that ulixertinib was we
Sullivan RJ, Infante JR, Janku F, et al. Cancer Discov. 2018;8(2):184-195.
The authors report two cases with the less common ERBB2 transmembrane domain (TMD) mutation. They were treated with afatinib and were confirmed achieving clinical benefits. There are other cases with the less common ERBB2 mutation as reported in The Cance
Yamamoto H, Toyooka S, Ninomiya T, et al. Oncologist. 2018;23(2):150-154
In a phase III (PALOMA-3) study, clinical activity of palbociclib plus fulvestrant was confirmed in advanced hormone receptor-positive, HER2-negative breast cancer patients whose tumor had previously progressed on endocrine treatment. In this study, the a
O'Leary B, Hrebien S, Morden JP, et al. Nat Commun. 2018, 1;9(1):896.
In the phase IIa (MyPathway) study, the patients with different advanced solid tumors harboring Her2, BRAF, EGFR or Hedgehog pathway alterations were treated with matching but are outside labeling targeted therapy. The results evaluated the efficacy of th
Hainsworth JD, Meric-Bernstam F, Swanton C, et al. J Clin Oncol. 2018, 20;36(6):536-542.
From 892 grandmother-granddaughter pairs of familial ovarian cancer samples, researchers found that the early-onset hereditary ovarian cancer gene may be located near the MAGEC3 gene on the X chromosome, and the male relatives with this mutation also have
Eng KH, Szender JB, Etter JL, et al. PLoS Genet. 2018, 15;14(2):e1007194
Based on the results of a phase II trial, erdafitinib, a pan-FGFR inhibitor, exhibited response in urothelial cancer patients who have progressed after standard chemotherapy with FGFR alterations.
Based on the study by University of California-San Diego Moores Cancer Center, genotype-matched therapy showed clinical benefit in rare cancer patients via genomic testing.
Researchers performed large pedigree exome analysis and confirmed that mutations in USP45 and ARID1A are associated with multiple myeloma.
The mainstay of treatments for metastatic pancreatic cancer is chemotherapy. A new targeted drug, entrectinib, shows the clinical benefit for metastatic pancreatic cancer with NTRK and ROS1 fusion.
J Clin Oncol 36, 2018 (suppl 4S; abstr 521)
In a phase II trial, patients with BRAF V600E-mutated anaplastic thyroid cancer were treated with the dabrafenib and trametinib combination therapy, resulting in clinical benefit and manageable toxicity.
J Clin Oncol, 2018 Jan 1;36(1):7-13 doi: 10.1200/JCO.2017.73.6785.